Clinical Trials
5 trialsNCT01169532 2021-02-21
Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma
Fox Chase Cancer Center
Phase 1 Completed
NCT00060632 2015-08-27
Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00060645 2015-08-27
Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00086125 2015-08-19
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00704054 2015-02-13
A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed